Skip to main content
ImmunityBio, Inc. (IBRX)
NASDAQ: IBRX · IEX Real-Time Price · USD
6.96
-0.70 (-9.08%)
May 20, 2024, 3:37 PM EDT - Market open

ImmunityBio Revenue

ImmunityBio had revenue of $302.00K in the twelve months ending March 31, 2024, down -48.46% year-over-year. Revenue in the quarter ending March 31, 2024 was $40.00K, a -88.89% decrease year-over-year. In the year 2023, ImmunityBio had annual revenue of $622.00K with 159.17% growth.

Revenue (ttm)
$302.00K
Revenue Growth
-48.46%
P/S Ratio
16,011.40
Revenue / Employee
$481
Employees
628
Market Cap
4.79B USD

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 2023622.00K382.00K159.17%
Dec 31, 2022240.00K-694.00K-74.30%
Dec 31, 2021934.00K329.00K54.38%
Dec 31, 2020605.00K-1.60M-72.52%
Dec 31, 20192.20M2.16M4,585.11%
Dec 31, 201847.00K2.00K4.44%
Dec 31, 201745.00K1,000.002.27%
Dec 31, 201644.00K-192.00K-81.36%
Dec 31, 2015236.00K-405.00K-63.18%
Dec 31, 2014641.00K41.00K6.83%
Dec 31, 2013600.00K--
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Organon & Co. 6.35B
Option Care Health 4.43B
Bausch + Lomb 4.31B
R1 RCM 2.31B
Lantheus Holdings 1.37B
Ionis Pharmaceuticals 776.62M
Apellis Pharmaceuticals 524.07M
Doximity 468.33M
Revenue Rankings

IBRX News

More News